Replies to post #7638 on BioCorRx Inc. (BICX)

[drugmanrx]

It will not be competitive in price.

Since naletrexone has been around for a long time how competitive in price can the new product be compared to the tablet form of naletrexone? Generally speaking a tablet form of a generic that has been around for a long time is absolutely dirt cheap.

Where it will have a market edge over tablet naltrexone is that patient compliance will significantly increase.

Since the BICX new version will be deliver by injection rather than by surgery the chance to get an insurance company to reimburse for the injection should be much easier.

[Fido]

Correct, insurance paying the fees has and continues to be an issue. As for the tablet being dirt cheap, it ain't effective if the patient isn't taking it. That was IMO the entire plus to the implant as it took the patient out of the loop to deliver the meds. I believe the same approach is for the injection even though I think that is only for 30 days. It takes the patient away from being able to decide, do I take the pill today or not, and thus increasing the chances of a successful treatment.

[Pip611]

Biocorrx is developing an improved version of injectable neltrexone. Search the board for the company conference call and presentation. That will answer many of your questions.